ChiCTR2500110847 版本V1.0 版本创建时间2025/10/21 17:15:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500110847 

最近更新日期:

Date of Last Refreshed on:

2025-10-21 17:15:35 

注册时间:

Date of Registration:

2025-10-21 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

急性胰腺炎患者居家自我管理变化轨迹和复发的纵向研究及影响因素分析

Public title:

A longitudinal study on the change trajectory of self-management and recurrence in patients with acute pancreatitis and analysis of influencing factors

注册题目简写:

English Acronym:

研究课题的正式科学名称:

急性胰腺炎患者居家自我管理变化轨迹和复发的纵向研究及影响因素分析

Scientific title:

A longitudinal study on the change trajectory of self-management and recurrence in patients with acute pancreatitis and analysis of influencing factors

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

翁远芳 

研究负责人:

翁远芳 

Applicant:

Weng Yuanfang 

Study leader:

Weng Yuanfang 

申请注册联系人电话:

Applicant telephone:

+86 13626059372

研究负责人电话:

Study leader's
telephone:

+86 13626059372

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1198344636@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1198344636@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省泉州市历城区东街248-252号

研究负责人通讯地址:

福建省泉州市历城区东街248-252号

Applicant address:

No. 248-252, East Street, Licheng District, Quanzhou City

Study leader's address:

No. 248-252, East Street, Licheng District, Quanzhou City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

泉州市第一医院

Applicant's institution:

Quanzhou First Hospital

研究负责人所在单位:

泉州市第一医院

Affiliation of the Leader:

Quanzhou First Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

泉一伦【2025】K236号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

泉州市第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of Quanzhou First Hospita

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-01 00:00:00

伦理委员会联系人:

柳江民

Contact Name of the ethic committee:

Liu Jiangmin

伦理委员会联系地址:

福建省泉州市历城区东街248-252号

Contact Address of the ethic committee:

No. 248-252, East Street, Licheng District, Quanzhou City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 595 22277157

伦理委员会联系人邮箱:

Contact email of the ethic committee:

13860799167@163.com

研究实施负责(组长)单位:

泉州市第一医院

Primary sponsor:

Quanzhou First Hospital

研究实施负责(组长)单位地址:

福建省泉州市历城区东街248-252号

Primary sponsor's address:

No. 248-252, East Street, Licheng District, Quanzhou City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建省

市(区县):

Country:

China

Province:

Fujian

City:

单位(医院):

泉州市第一医院

具体地址:

福建省泉州市历城区东街248-252号

Institution
hospital:

Quanzhou First Hospital

Address:

No. 248-252, East Street, Licheng District, Quanzhou City

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected topic

研究疾病:

急性胰腺炎  

Target disease:

Acute pancreatitis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

(1)通过潜变量增长模型识别首发胰腺炎患者出院后6个月内的自我管理一般变化轨迹并基于潜类别增长混合模型识别其不同亚群的异质性发展轨迹的潜在亚组;探讨首发胰腺炎患者一般人口学、疾病相关资料和相关变量对不同潜类别自我管理轨迹的预测作用。 (2)探究急性胰腺炎患者疾病复发过程中自我管理的真实体验,了解其在疾病管理中遇到的问题和需求,分析复发患者自我管理轨迹的影响因素。  

Objectives of Study:

1. Identify the general change trajectory of self-management within 6 months after discharge in patients with first-onset pancreatitis through latent growth models, and based on latent class growth mixture models, identify the potential subgroups of heterogeneous development trajectories of different subgroups; explore the predictive effects of general demographic, disease-related data and related variables of patients with first-onset pancreatitis on different latent class self-management trajectories. 2. Explore the real experiences of self-management during the disease recurrence process in patients with acute pancreatitis, understand the problems and needs they encounter in disease management, and analyze the influencing factors of self-management trajectories in recurrent patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18 岁; 2.符合《中国急性胰腺炎诊治指南(2021 年)》[5]中关于急性胰腺炎的诊断标准的患者,且为首次发病。AP 诊断标准包括以下 3 项,符合其中 2 项即可诊断为 AP:①上腹部持续性疼痛。②血清淀粉酶和(或)脂肪酶浓度至少高于正常上限值 3 倍。③腹部影像学检查结果显示符合急性胰腺炎影像学改变(胰腺水肿或胰周渗出积液); 3.意识清楚,过去或现在无严重精神病史、认知障碍; 4.自愿同意参加研究。

Inclusion criteria

1. Age >= 18 years; 2. Patients who meet the diagnostic criteria for acute pancreatitis according to the "Chinese Guidelines for the Diagnosis and Treatment of Acute Pancreatitis (2021)" [5], and who are experiencing their first episode. The diagnostic criteria for AP include the following three items, with a diagnosis of AP confirmed if any two are met: (1) Persistent pain in the upper abdomen; (2) Serum amylase and/or lipase levels at least three times the upper limit of normal; (3) Abdominal imaging results showing changes consistent with acute pancreatitis (pancreatic edema or peripancreatic fluid collection); 3. Conscious, with no history of severe mental illness or cognitive impairment, past or present; 4. Voluntarily agrees to participate in the study.

排除标准:

1.需外科手术治疗的胰腺炎;
2.患有其他严重疾病者,如心、肝、肺、肾功能不全及恶性肿瘤等;
3.处于妊娠期或哺乳期;

Exclusion criteria:

1.Pancreatitis requiring surgical treatment; 2.Those with other serious diseases, such as heart, liver, lung, and kidney insufficiency, as well as malignant tumors; 3.During pregnancy or lactation.

研究实施时间:

Study execute time:

From 2025-08-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-08-01 00:00:00 To 2027-12-01 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

236

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建省 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

泉州市第一医院 

单位级别:

三级甲等 

Institution
hospital:

Quanzhou First Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

福建省 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

晋江市医院(上海市第六人民医院福建医院) 

单位级别:

三级医院 

Institution
hospital:

Jinjiang Municipal Hospital(Shanghai Sixth People's Hospital Fujian Campus)

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

福建省 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

福建医科大学附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated hospital of Fujian Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

社会支持度

指标类型:

次要指标

Outcome:

Social support

Type:

Secondary indicator

测量时间点:

住院期间、出院1周、1、3、6、12个月

测量方法:

领悟社会支持量表

Measure time point of outcome:

During hospitalization, one week, one , three , six and twelve months after discharge

Measure method:

Questionnaire survey, telephone follow-up

指标中文名:

成年人健康自我管理

指标类型:

主要指标

Outcome:

Self-management ability for health

Type:

Primary indicator

测量时间点:

住院期间、出院1周、1、3、6、12个月

测量方法:

成年人健康自我管理能力

Measure time point of outcome:

During hospitalization, one week, one , three , six and twelve months after discharge

Measure method:

Questionnaire survey, telephone follow-up

指标中文名:

自我效能感

指标类型:

次要指标

Outcome:

General self-efficacy

Type:

Secondary indicator

测量时间点:

住院期间、出院1周、1、3、6、12个月

测量方法:

一般自我效能感量表

Measure time point of outcome:

During hospitalization, one week, one , three , six and twelve months after discharge

Measure method:

Questionnaire survey, telephone follow-up

指标中文名:

疾病感知状况

指标类型:

次要指标

Outcome:

Perception of illness

Type:

Secondary indicator

测量时间点:

住院期间、出院1周、1、3、6、12个月

测量方法:

简化版疾病感知问卷

Measure time point of outcome:

During hospitalization, one week, one , three , six and twelve months after discharge

Measure method:

Questionnaire survey, telephone follow-up

指标中文名:

心理弹性

指标类型:

次要指标

Outcome:

Mental elasticity

Type:

Secondary indicator

测量时间点:

住院期间、出院1周、1、3、6、12个月

测量方法:

心理弹性量表简版

Measure time point of outcome:

During hospitalization, one week, one , three , six and twelve months after discharge

Measure method:

Questionnaire survey, telephone follow-up

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后一年内,国家生物信息中心 https://ngdc.cncb.ac.cn/gsa

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within one year of publication, China Nation center for Bioinformation https://ngdc.cncb.ac.cn/gsa.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用纸质问卷进行数据采集、录入Excel 2019进行管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper questionnaire, Excel system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-10-21 17:15:35